In the Claims

The listing of claims will replace all prior versions and listings of claims in the application.

Listings of claims

1. (original) A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



I

wherein

n is 1 or 2;

R^1 is selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, $-CH_2-R^8$, $-C(=O)-NH-R^7$, $-C(=S)-NH-R^7$, $-C(=O)-O-R^7$, $-S(=O)_2-R^6$, and $-C(=O)-R^5$, wherein R^5, R^6, R^7 and R^8 are independantly selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl used in defining R^1, R^5, R^6, R^7 or R^8 are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, C_{1-6}alkyl, $-C(=O)-R$, $-C(=O)-OR$, $-C(=O)-NHR$, -SR, -SH, halogenated C_{1-6}alkyl, -CN, $-NO_2$, C_{1-6}alkoxy and halogen, or disubstituted with $-O-CH_2-O-$ to form a fused ring;

R^2 is selected from –H and C_{1-6}alkyl;

R^3 and R^4 are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl are optionally substituted with one or more groups selected from –OH, -CHO, $-NH_2$, -NHR, $-NR_2$, C_{1-6}alkyl, $-C(=O)-OR$, $-C(=O)-NHR$, -SR, -SH, halogenated C_{1-6}alkyl, -CN, $-NO_2$, C_{1-6}alkoxy and halogen; or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more

groups selected from benzyl, –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen;

Ar is selected from C_{6-10}aryl and C_{3-6}heteroaryl, wherein said C_{6-10}aryl and C_{3-6}heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen; and

R is C_{1-6}alkyl.

2. (original) A compound according to claim 1,

wherein n is 1 or 2;

R^1 is selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, -CH_2-R^8, -C(=O)-NH-R^7, -C(=S)-NH-R^7, -$S(=O)_2$-R^6, and -C(=O)-R^5, wherein R^5, R^6, R^7 and $R^8$are independantly selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-2}alkyl, phenyl, phenyl-C_{1-2}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-2}alkyl, wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}alkyl, phenyl, phenyl-C_{1-2}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-2}alkyl used in defining R^1, R^5, R^6, R^7or R^8 are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-3}alkyl, -C(=O)-R, -C(=O)-OR, -SR, -CF_3, -CN, methoxy, ethoxy, fluoro and chloro, or disubstituted with –O-CH_2-O- to form a fused ring;

R^2 is selected from –H, methyl and ethyl;

R^3 and R^4 are independently selected from –H, C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-2}alky, phenyl, phenyl-C_{1-2}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-2}alkyl, wherein said C_{1-4}alkyl, C_{2-4}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-2}alky, phenyl, phenyl-C_{1-2}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-2}alkyl are optionally substituted with one or more groups selected from -CHO, -NH_2, -NHR, -NR_2, C_{1-3}alkyl, -C(=O)-OR, -CF_3, -CN, methoxy, ethoxy, fluoro and chloro; or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring, wherein said heterocycloalkyl ring is optionally substituted with one or more groups selected from benzyl, -CHO, C_{1-3}alkyl, -C(=O)-OR, -CF_3, -CN, methoxy, ethoxy, fluoro and chloro;

Ar is selected from phenyl and five or six-membered C_{3-5}heteroaryl, wherein said phenyl and five or six-membered C_{3-5}heteroaryl are optionally substituted with one or more groups selected from C_{1-3}alkyl, -C(=O)-OR, -CF_3, -CN, methoxy, ethoxy, fluoro and chloro; and

R is C_{1-3}alkyl.

3. (original) A compound according to claim 1,

wherein n is 1 or 2;

R^1 is selected from $-CH_2-R^8$, $-C(=O)-NH-R^7$, $-C(=S)-NH-R^7$, $-S(=O)_2-R^6$, and $-C(=O)-R^5$, wherein R^5, R^6, R^7 and $R^8$are independantly selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-2}alkyl, phenyl, benzyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-2}alkyl, phenyl, benzyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-2}alkyl, C_{3-6}heteroaryl are optionally substituted with one or more groups selected from methyl, ethyl, $-C(=O)-CH_3$, $-C(=O)-OCH_3$, $-C(=O)-OCH_2-CH_3$, $-SCH_3$, -CN, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with $-O-CH_2-O-$ to form a fused ring;

R^2 is selected from –H, methyl and ethyl;

R^3 and R^4 are independently selected from –H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, pyridyl, furyl and thienyl, wherein said phenyl, pyridyl, furyl and thienyl are optionally substituted with one or more methoxy or ethoxy.

4. (original) A compound according to claim 1,

wherein n is 1 or 2;

R^1 is selected from $-CH_2-R^8$, $-C(=O)-NH-R^7$, $-C(=S)-NH-R^7$, $-S(=O)_2-R^6$, and $-C(=O)-R^5$, wherein R^5, R^6, R^7 and $R^8$are independantly selected from methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl, wherein said methyl, ethyl, isopropyl, 1-propyl, 2-methyl-1-propyl, 3-methyl-1-butyl, 2-ethyl-1-butyl, 1-butyl, 1-propen-3-yl, 4-methyl-2-penten-1-yl, 3-methyl-2-buten-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentyl-methyl, phenyl, benzyl, 4-morpholinyl-ethyl, tetrahydrothiopyran-4-yl-

ethyl, furyl, isoxazolyl, pyridyl, thienyl, pyrazolyl, imidazolyl, and pyrrolyl are optionally substituted with one or more groups selected from methyl, ethyl, -C(=O)-CH_3, -C(=O)-OCH_3, -C(=O)-OCH_2-CH_3, -SCH_3, -CN, methoxy, ethoxy, fluoro and chloro, or said phenyl or benzyl is optionally disubstituted with –O-CH_2-O- to form a fused ring;

R^2 is selected from –H, methyl and ethyl;

R^3 and R^4 are independently selected from –H, methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl, wherein said methyl, ethyl, propenyl, cyclopropyl-methyl, cyclobutyl, cyclopentyl, tetrahydrofuryl-methyl, furyl-methyl, pyridyl-methyl, thiomorpholinyl-ethyl, pyrrolidinyl-methyl, pyrrolidinyl-ethyl, thienyl-methyl are optionally substituted with one or more groups selected from dimethylamino, diethylamino, diisopropylamino, methyl, ethyl, methoxy, or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycloalkyl ring selected from piperidine, azetidine, piperazine, pyrrolidine and morpholine, wherein said piperidine, azetidine, piperazine, pyrrolidine and morpholine is optionally substituted with one or more groups selected from benzyl, methyl and -CHO; and

Ar is selected from phenyl, 4-ethoxyphenyl, 4-methoxyphenyl, pyridyl, furyl and thienyl.

5. (original) A compound according to claim 1, wherein the compound is selected from:
1-Benzoyl-4-phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
1-Benzoyl-*N*-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N,*N*-Diethyl-4-phenyl-1-(phenylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
1-Benzyl-*N*-[2-(diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-1-(2-furylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-4-phenyl-1-(pyridin-3-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-1-[(1-methyl-1*H*-pyrrol-2-yl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
1-(3-Furylmethyl)-8-(morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

N-[2-(Diisopropylamino)ethyl]-1-[(5-ethyl-2-furyl)methyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-1-(thien-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N,*N*-Diethyl-4-phenyl-1-(thien-2-ylsulfonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
and pharmaceutically acceptable salts thereof.

6-7. (cancelled)

8. (currently amended) A pharmaceutical composition comprising a compound according to ~~any one of claims 1-5~~claim 1 and a pharmaceutically acceptable carrier.

9. (currently amended) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to ~~any one of claims 1-5~~claim 1.

10. (currently amended) A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to ~~any one of claims 1-5~~claim 1.

11. (original) A process for preparing a compound of formula I, comprising:



I

reacting a compound of formula II with a compound selected from R^5-C(=O)-Cl, R^6-$S(=O)_2$-Cl, R^7-NCO, R^7-NCS and R^8CHO:



II

wherein

n is 1 or 2;

R^1 is selected from -CH_2-R^8, -C(=O)-NH-R^7, -C(=S)-NH-R^7, -S(=O)$_2$-R^6, and -C(=O)-R^5, wherein R^5, R^6, R^7 and R^8 are independantly selected from C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-R, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy and halogen, or disubstituted with –O-CH_2-O- to form a fused ring;

R^2 is selected from –H and C_{1-6}alkyl;

R^3 and R^4 are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy and halogen; or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen;

Ar is selected from C_{6-10}aryl and C_{3-6}heteroaryl, wherein said C_{6-10}aryl and C_{3-6}heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen; and

R is C_{1-6}alkyl.

12. (original) A process for preparing a compound of formula I, comprising:



I

reacting a compound of formula III with R^3R^4NH:



III

wherein

n is 1 or 2;

R^1 is selected from –C(=O)-O-C_{1-6}alkyl and –C(=O)-O-C_{2-6}alkenyl;

R^2 is selected from –H and C_{1-6}alkyl;

R^3 and R^4 are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy and halogen; or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen;

Ar is selected from C_{6-10}aryl and C_{3-6}heteroaryl, wherein said C_{6-10}aryl and C_{3-6}heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen; and

R is C_{1-6}alkyl.

13. (original) A process for preparing a compound of formula IV, comprising:



IV

reacting a compound of formula V with a compound of formula VI:



V

VI

wherein

n is 1 or 2;

R^1 is selected from –C(=O)-O-C_{1-6}alkyl and –C(=O)-O-C_{2-6}alkenyl;

R^9 is C_{1-6}alkyl;

Ar is selected from C_{6-10}aryl and C_{3-6}heteroaryl, wherein said C_{6-10}aryl and C_{3-6}heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen; and

R is C_{1-6}alkyl.

14. (original) A compound of formula II:



II

wherein

n is 1 or 2;

R^2 is selected from –H and C_{1-6}alkyl;

R^3 and R^4 are independently selected from –H, C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl, wherein said C_{1-6}alkyl, C_{2-6}alkenyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkyl-C_{1-4}alkyl, C_{6-10}aryl, C_{6-10}aryl-C_{1-4}alkyl, C_{3-6}heterocycloalkyl, C_{3-6}heterocycloalkyl-C_{1-4}alkyl, C_{3-6}heteroaryl, and C_{3-6}heteroaryl-C_{1-4}alkyl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy and halogen; or R^3 and R^4 together with the nitrogen connected thereto in formula I form a heterocycle ring, wherein said heterocycle ring is optionally substituted with one or more groups selected from benzyl, –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen;

Ar is selected from C_{6-10}aryl and C_{3-6}heteroaryl, wherein said C_{6-10}aryl and C_{3-6}heteroaryl are optionally substituted with one or more groups selected from –OH, -CHO, -NH_2, -NHR, -NR_2, C_{1-6}alkyl, -C(=O)-OR, -C(=O)-NHR, -SR, -SH, halogenated C_{1-6}alkyl, -CN, -NO_2, C_{1-6}alkoxy, and halogen; and

R is C_{1-6}alkyl.

15. (original) A compound according to claim 14, wherein the compound is selected from:
8-[(4-Methylpiperazin-1-yl)carbonyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
8-(Morpholin-4-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
4-Phenyl-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-Phenyl-*N*-(tetrahydrofuran-2-ylmethyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N,*N*-Diethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-(4-Ethoxyphenyl)-8-[(4-methylpiperazin-1-yl)carbonyl]-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
4-(4-Ethoxyphenyl)-8-(morpholin-4-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;

4-(4-Ethoxyphenyl)-8-(pyrrolidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-(4-Ethoxyphenyl)-*N*-(2-furylmethyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-(2-Methoxyethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
(4-(4-Ethoxyphenyl)-*N*,*N*-diethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-[2-(Diethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-4-methyl-;
Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;
Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-methyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[(1-ethyl-2-pyrrolidinyl)methyl]-2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(4-methoxyphenyl)-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-*N*-(2-pyridinylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;

1-Piperazinecarboxaldehyde, 4-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-;
1-Piperazinecarboxaldehyde, 4-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-;
Piperazine, 1-[(2,3,3a,4,5,9b-hexahydro-4-phenyl-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl)carbonyl]-4-(phenylmethyl)-;
Piperazine, 1-[[2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-1*H*-pyrrolo[3,2-*c*]quinolin-8-yl]carbonyl]-4-(phenylmethyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-[bis(1-methylethyl)amino]ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(dimethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-*N*-methyl-4-phenyl-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, *N*-[2-(diethylamino)ethyl]-2,3,3a,4,5,9b-hexahydro-*N*-methyl-4-(2-pyridinyl)-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-phenyl-*N*-[2-(4-thiomorpholinyl)ethyl]-;
1*H*-Pyrrolo[3,2-*c*]quinoline-8-carboxamide, 2,3,3a,4,5,9b-hexahydro-4-(2-pyridinyl)-*N*-[2-(4-thiomorpholinyl)ethyl]-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-thienylmethyl)-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-*N*,*N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-;

Benzo[*h*][1,6]naphthyridine-9-carboxamide, 5-(4-ethoxyphenyl)-1,2,3,4,4a,5,6,10b-octahydro-*N*-[2-(1-pyrrolidinyl)ethyl]-;
Pyrrolidine, 1-[(1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopropyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-*N*-(2-thienylmethyl)-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-*N*-[(5-methyl-2-furanyl)methyl]-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*,*N*-diethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-*N*-[2-(1-pyrrolidinyl)ethyl]-;
Pyrrolidine, 1-[(6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenylbenzo[*h*][1,6]naphthyridin-9-yl)carbonyl]-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, 6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-*N*-(2-methoxyethyl)-5-phenyl-;
Benzo[*h*][1,6]naphthyridine-9-carboxamide, *N*-cyclopentyl-6-ethyl-1,2,3,4,4a,5,6,10b-octahydro-5-phenyl-;
N-Cyclopropyl-6-ethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;
6-Ethyl-5-phenyl-*N*-(thien-2-ylmethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;
6-Ethyl-*N*-[(5-methyl-2-furyl)methyl]-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;
N,*N*,6-Triethyl-5-phenyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;
6-Ethyl-5-phenyl-*N*-(2-pyrrolidin-1-ylethyl)-1,2,3,4,4a,5,6,10b-octahydrobenzo[*h*]-1,6-naphthyridine-9-carboxamide;
4-(4-Ethoxyphenyl)-*N*,*N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

4-(4-Ethoxyphenyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-(Cyclopropylmethyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclobutyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclopropyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Allyl-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-(4-Ethoxyphenyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
8-(Azetidin-1-ylcarbonyl)-4-(4-ethoxyphenyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N,*N*-Dimethyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Methyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-(Cyclopropylmethyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclobutyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclopropyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
(*N*-Allyl-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-Phenyl-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
8-(Azetidin-1-ylcarbonyl)-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
4-(2-Furyl)-*N*,*N*-dimethyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-(2-Furyl)-*N*-methyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-(Cyclopropylmethyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclobutyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclopropyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Allyl-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
4-(2-Furyl)-8-(piperidin-1-ylcarbonyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
8-(Azetidin-1-ylcarbonyl)-4-(2-furyl)-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N,*N*-Dimethyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Methyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;

N-(Cyclopropylmethyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclobutyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Cyclopropyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
N-Allyl-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide;
8-(Piperidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
8-(Azetidin-1-ylcarbonyl)-4-thien-3-yl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline;
N-[2-(Dimethylamino)ethyl]-4-phenyl-2,3,3a,4,5,9b-hexahydro-1*H*-pyrrolo[3,2-*c*]quinoline-8-carboxamide; and pharmaceutically acceptable salts thereof.

16. (new) A method for the therapy of anxiety in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.